Interference of Monovalent, Bivalent, and Trivalent Oral Poliovirus Vaccines on Monovalent Rotavirus Vaccine Immunogenicity in Rural Bangladesh

Clinical Infectious Diseases

Volumn 62, Issue 2, 2016, Pages 150-156

  Emperador, Devy M ^a   Velasquez, Daniel E ^a   Estivariz, Concepcion F ^a   Lopman, Ben ^a   Jiang, Baoming ^a   Parashar, Umesh ^a   Anand, Abhijeet ^a   Zaman, Khalequ ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

Author keywords

OPV; oral polio vaccine; Rotarix; rotavirus vaccine; vaccine interference

Indexed keywords

BIVALENT ORAL POLIOVIRUS VACCINE; IMMUNOGLOBULIN A; MONOVALENT ORAL POLIOVIRUS VACCINE; MONOVALENT ROTAVIRUS VACCINE; ORAL POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; TRIVALENT ORAL POLIOVIRUS VACCINE; UNCLASSIFIED DRUG; LIVE VACCINE; RIX4414 VACCINE; VIRUS ANTIBODY;

ADULT; ARTICLE; BANGLADESH; BREAST FEEDING; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOGENICITY; MALE; MALNUTRITION; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; ROTAVIRUS A; ROTAVIRUS INFECTION; RURAL AREA; SEROCONVERSION; TREATMENT DURATION; VACCINATION; BLOOD; DRUG INTERACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; INFANT; RANDOMIZED CONTROLLED TRIAL; RURAL POPULATION;

ANTIBODIES, VIRAL; BANGLADESH; DRUG INTERACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN A; INFANT; POLIOVIRUS VACCINE, ORAL; ROTAVIRUS VACCINES; RURAL POPULATION; VACCINES, ATTENUATED;

EID: 84960083163     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ807     Document Type: Article

References (35)

1. World Health Organization. Rotavirus vaccines WHO position paper-January 2013. Wkly Epidemiol Rec 2013; 88:49-64.
2. Tate JE, Burton AH, Boschi-Pinto C, et al. 2008 estimate of worldwide rotavirusassociated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect Dis 2012; 12:136-41.
3. Jiang V, Jiang B, Tate J, Parashar UD, Patel M. Performance of rotavirus vaccines in developed and developing countries. Hum Vaccin 2010; 6:532-42.
4. Soares-Weiser K, Maclehose H, Bergman H, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev 2012; 11:1-178.
5. Rennels MB. Concurrent oral poliovirus and rhesus-human assortant rotavirus vaccination: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines. J Infect Dis 1996; 173:306-13.
6. Rennels MB. Influence of breast-feeding and oral poliovirus vaccine on immunogenicity and efficacy of rotavirus vaccine. J Infect Dis 1996; 174(suppl 1):S107-11.
7. Ciarlet M, San-Grosso R, Yuan G, et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral polio vaccine. Pediatr Infect Dis J 2008; 27:874-80.
8. Zaman K, Sack DA, Arifeen SE, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009; 27:1333-9.
9. Steele AD, De Vos B, Tumbo J, et al. Co-administration study of South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2010; 28:6542-8.
10. Tregnaghi MW, Abate HJ, Valencia A, et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J 2011; 30:e103-8.
11. Patel M, Steele AD, Parashar UD. Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines. Vaccine 2012; 30S:A30-5.
12. Maldonado YA, Pena-Cruz V, de la Luz Sanchez M, et al. Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. JID 1997; 175:545-53.
13. Okayasu H, Sutter RW, Czerkinsky C, Ogra PL. Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission. Vaccine 2011; 29:8205-14.
14. World Health Organization. Polio vaccines: WHO position paper, January 2014. Wkly Epidemiol Rec 2014; 9:73-92.
15. World Health Organization. Polio eradication & endgame strategic plan 2013-2018. Geneva, Switzerland: WHO Press, 2013.
16. Estivariz CF, Anand A, Gary HE Jr, et al. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomized, control trial. Lancet Infect Dis 2015; 15:898-904.
17. Moon SS,Wang Y, Shane AL, et al. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J 2010; 29:919-23.
18. Groome MJ,Moon SS, Velasquez D, et al. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: A randomized trial inHIV-uninfected infants in Soweto, South Africa. Bull World Health Organ 2014; 92:238-45.
19. Wang H, Moon S, Wang Y, Jiang B. Multiple virus infection alters rotavirus replication and expression of cytokines and toll-like receptors in intestinal epithelial cells. Virus Res 2012; 167:48-55.
20. Franco MA, Angel J, Greenberg HB. Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006; 24:2718-31.
21. Angel J, Franco MA, Greenberg HB. Rotavirus immune responses and correlates of protection. Curr Opin Virol 2012; 2:419-25.
22. Jiang B, Snipes-Magaldi L, Dennehy P, et al. Cytokines as mediators for or effectors against rotavirus disease in children. Clin Vaccine Immunol 2003; 10:995-1001.
23. Sartono E, Lisse IM, Terveer EM, et al. Oral polio vaccine influences the immune response to BCG vaccination: A natural experiment. PLoS One 2010; 5:e10328.
24. Patel M, Glass RI, Jiang B, Santosham M, Lopman B, Parashar U. A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis 2013; 208:284-94.
25. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most. J Infect Dis 2009; 200(suppl 1):S39-48.
26. Appaihgari MB, Glass R, Singh S, et al. Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. Vaccine 2014; 32:651-6.
27. Velasquez D, Bautista A, Esparza M, et al. Association between breastfeeding and immunogenicity of Rotarix in Mexican infants [abstract W12-8]. In: Scientific program and abstracts of the 33rd Annual Meeting of the American Society for Virology. (Fort Collins). Toledo, OH: American Society for Virology, 2014:110.
28. Becker-Dreps SSV, Velasquez D, Moon SS, Hudgens MG, Zambrana LE, Jiang B. Rotavirus specific IgG antibodies from mother's serum may inhibit infant immune responses to the pentavalent rotavirus vaccine. Pediatr Infect Dis 2015; 34:115-6.
29. Zaman K, Yunus MD, Faruque ASG, et al. Surveillance of rotavirus in a rural diarrhoea treatment centre in Bangladesh, 2000-2006. Vaccine 2009; 27S:F31-4.
30. Shin S, Anh DD, Zaman K, et al. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine 2012; 30S:A106-13.
31. Narang A, Bose A, Pandit AN, et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Hum Vaccin 2009; 5:414-9.
32. Dennehy PH, Bertrand HR, Silas PE, Damaso S, Friedland LR, Abu-Elyazeed R. Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States. Pediatrics 2008; 122:e1062-6.
33. Vesikari T, Karvonen A, Prymula R, et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine 2010; 28:5272-9.
34. Tate JE, Patel MM, Steele AD, et al. Global impact of rotavirus vaccines. Expert Rev Vaccines 2010; 9:395-407.
35. O'Ryan M, Lucero Y, Linhares AC. Rotarix: vaccine performance 6 years postlicensure. Expert Rev Vaccines 2011; 10:1645-16.